20%
of the population experiences moderate to severe chronic pain
Revolutioning pain treatment
Dolinnov aims to redefine the standard of care in pain management and bring hope to millions worldwide.
First
innovative therapeutic strategy utilizing an Lipid antisense oligonucleotide (LASO) to target a regulator at the dorsal root ganglion (DRG)
FXYD2
A novel therapeutic target in chronic pain, acting through the regulation of the Na+/K+ ATPase pump to modulate pain signaling pathways.
Our mission
At Dolinnov, we are committed to becoming a leading force in the management of chronic pain.
As a science-driven and innovation-focused organization, our mission is to transform the lives of patients by delivering cutting-edge solutions for complex and often unbearable conditions.
Transforming innovation into the next generation of pain relief
Innovative target
- The FXYD2 protein, also known as the gamma subunit of the Na+/K+-ATPase, plays a regulatory role in ion transport and neuronal excitability.
- As a peripheral nervous system target, FXYD2 offers a unique opportunity for precise therapeutic intervention, minimizing potential side effects on central nervous system functions.
Precision therapeutic modality
- Dolinnov is the first company worldwide to develop a lipid antisense oligonucleotide (L-ASO) therapy specifically targeting pain.
- Our patented proprietary conjugated L-ASO chemistry enables groundbreaking efficacy.
A Broad Spectrum of Indications
- Our new therapeutic approach targets both neuropathic and inflammatory pain, offering a comprehensive solution for chronic pain management.
- Priority indications include Chemotherapy-Induced Peripheral Neuropathy (CIPN)
What immediately inspired me to join this project was its groundbreaking approach to targeting this mechanism—a causal and 'circuit-breaking' strategy for pain management. Combined with the exceptional quality of the underlying science, it redefines treatment paradigms, effectively addressing the primary barriers to patient care.
It is the extraordinary motivation of a researcher to transform a groundbreaking academic discovery from my thesis into a preclinical reality, with the goal of revolutionizing patient care and advancing the frontiers of medicine.
Dolinnov is a unique opportunity to convert a high-level academic scientific project into a groundbreaking enterprise. I am committed to dedicating my full energy to turning this project into a clinical reality that will make a difference for patients.
Investing in Dolinnov is above all about supporting a highly mature, scientific disruptive project with the potential to deliver game-changing treatment solutions. It also means placing trust in a strong and dedicated team capable of making this vision a clinical reality.
Dolinnov is a unique opportunity to convert a high-level academic scientific project into a groundbreaking enterprise. I am committed to dedicating my full energy to turning this project into a clinical reality that will make a difference for patients.
It is the extraordinary motivation of a researcher to transform a groundbreaking academic discovery from my thesis into a preclinical reality, with the goal of revolutionizing patient care and advancing the frontiers of medicine.
What immediately inspired me to join this project was its groundbreaking approach to targeting this mechanism—a causal and 'circuit-breaking' strategy for pain management. Combined with the exceptional quality of the underlying science, it redefines treatment paradigms, effectively addressing the primary barriers to patient care.
Investing in Dolinnov is above all about supporting a highly mature, scientific disruptive project with the potential to deliver game-changing treatment solutions. It also means placing trust in a strong and dedicated team capable of making this vision a clinical reality.
Partners supporting the project
Design with by the gang